Search

Your search keyword '"Wu, M. -S"' showing total 25 results
Start Over Author "Wu, M. -S" Publisher wiley
25 results on '"Wu, M. -S"'

1. TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study

Author

Yan, K X, Zhang, Y J, Han, L, Huang, Q, Zhang, Z H, Fang, X, Zheng, Z Z, Yawalkar, Nikhil, Chang, Y L, Zhang, Q, Jin, L, Qian, D F, Li, X Y, Wu, M S, Xu, Q H, Zhang, X J, and Xu, J H

Subjects
610 Medicine & health
Abstract

BACKGROUND Methotrexate (MTX) is an efficacious treatment for psoriasis; however, its widespread application is limited by its unpredictable efficacy. OBJECTIVES To investigate the association of clinical factors and variants of psoriasis susceptibility genes with clinical responses to MTX in a prospective cohort. METHODS A total of 221 patients with psoriasis were recruited. Patients who achieved Psoriasis Area and Severity Index (PASI) improvement ≥ 75% at week 12 were defined as responders, whereas those with PASI improvement < 50% were defined as nonresponders. In 90 screening patients, genetic variants for 18 single-nucleotide polymorphisms in 14 susceptibility genes, and HLA-Cw6 status were initially compared for responders and nonresponders. Statistically significant associations in genetic variants were verified in all 221 patients. RESULTS Overall, 49% and 45% of patients achieved PASI 75 improvement during screening and verification stages, respectively. Concomitant arthritis with psoriasis and high body mass index (BMI) negatively affect the efficacy of MTX. TT genotype of rs10036748 in TNIP1 was significantly associated with PASI 75 response at week 12 (54% and 37%, P < 0·05). A significantly higher PASI 90 response was observed in patients with TT genotype of rs10036748 (27% vs. 12%, P < 0·01) and TC/TT genotype of rs4112788 in LCE3D (25% vs. 13%, P < 0·05) at week 12 compared with those who had other genotypes. After adjustment for all confounding factors, only BMI (P < 0·05), arthritis (P < 0·05) and genotype of rs10036748 (P < 0·05) were significantly associated with clinical responses to MTX. CONCLUSIONS Patients with psoriasis with TT genotype of rs10036748 in TNIP1, with lower BMI, without arthritis will achieve a better response to MTX.

Published
2019
Full Text
View/download PDF

7. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers

Author

Chen, C.-C., primary, Lee, J.-Y., additional, Fang, Y.-J., additional, Hsu, S.-J., additional, Han, M.-l., additional, Tseng, P.-H., additional, Liou, J.-M., additional, Hu, F.-C., additional, Lin, T.-l., additional, Wu, M.-S., additional, Wang, H.-P., additional, and Lin, J.-T., additional

Published
2012
Full Text
View/download PDF

13. Differential response to H. pylori eradication therapy of co‐existing diffuse large B‐cell lymphoma and MALT lymphoma of stomach—significance of tumour cell clonality and BCL10 expression

Author

Kuo, S‐H, primary, Chen, L‐T, additional, Wu, M‐S, additional, Kuo, K‐T, additional, Yeh, K‐H, additional, Doong, S‐L, additional, Yeh, P‐Y, additional, Hsu, H‐C, additional, Tzeng, Y‐S, additional, Lin, C‐W, additional, Lin, J‐T, additional, and Cheng, A‐L, additional

Published
2006
Full Text
View/download PDF

24. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.

Author

Wagner JA, Larson PJ, Weiss S, Miller JL, Doebber TW, Wu MS, Moller DE, and Gottesdiener KM

Subjects
Adolescent, Adult, Biomarkers blood, Cross-Over Studies, Drug Interactions, Humans, Male, Pilot Projects, Rosiglitazone, Blood Glucose metabolism, Fenofibrate pharmacology, Hypolipidemic Agents pharmacology, Lipids blood, PPAR alpha agonists, PPAR gamma agonists, Thiazolidinediones pharmacology
Abstract

This open-label, randomized, placebo-controlled, incomplete-block, 3-period crossover pilot study investigated the effects of peroxisome proliferator-activated receptor alpha- and gamma-agonists on biomarkers of lipid and glucose metabolism in 12 nondiabetic subjects. Plasma samples were collected before and after each 14-day treatment with placebo, fenofibrate (201 mg/d), rosiglitazone (4 mg twice daily), and combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily). Except for triglycerides (P < .042) and free fatty acids (P < .074), no significant interaction was demonstrated between fenofibrate and rosiglitazone; thus, the effect due to each drug alone was evaluated (presence/absence of drug). Fenofibrate significantly (P < .050) increased lipoprotein lipase activity (35%) and decreased apolipoproteins B (13%) and C-III (20%). Rosiglitazone significantly (P < .050) decreased fasting glucose (7.3%) and increased apolipoprotein C-III (19%) and adiponectin (137%). Fenofibrate and rosiglitazone also produced effects on triglycerides and free fatty acids, but it was not possible to determine if these effects were synergistic in nature.

Published
2005
Full Text
View/download PDF

25. Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs.

Author

Yu HY, Wu MS, and Shen YZ

Subjects
Animals, Blood Proteins metabolism, Guinea Pigs, Infusions, Intravenous, Male, Mathematics, Metabolic Clearance Rate, Valproic Acid blood, Liver metabolism, Valproic Acid metabolism, Valproic Acid pharmacokinetics
Abstract

The plasma clearance and metabolic rate characteristics of valproic acid (VPA) were studied using guinea-pigs placed on various (0.08-9 mumol ml-1 = 11-1303 micrograms ml-1) steady-state plasma concentrations (Css) by constant intravenous (i.v.) infusion. The total clearance (CL) was significantly decreased at plasma concentration of 0.61 mumol ml-1 (88 micrograms ml-1). The metabolic clearance of VPA was apparently biphasic. The maximum metabolic rate (Vmax) and the Michaelis-Menten constant (Km) for the primary (Vmax1, Km1) and the secondary (Vmax2, Km2) pathways were Vmax1 = 1.52 mumol min-1 kg-1, Km1 = 0.15 mumol ml-1, Vmax2 = 24.98 mumol min-1 kg-1 and Km2 = 11.70 mumol ml-1, respectively. The Km1 value was within clinical therapeutic concentration range. The formation of conjugated VPA (cjVPA) metabolite in liver was shown to be saturable. Plasma protein binding of VPA was also nonlinear. The dose-dependent decrease in metabolic clearance was counterbalanced by the increased unbound fraction (fu), resulting in a relatively constant apparent clearance of VPA over a wide concentration range. The hepatic concentration of VPA was not significantly different from the plasma unbound concentration, again over a wide concentration range. The biliary and hepatic concentrations of VPA were not significantly different; but the concentration ratio of cjVPA in bile compared with that of VPA in liver decreased against hepatic concentration of VPA, which suggests a saturable conjugation rate. The Km value estimated from hepatic cjVPA production as a function of plasma VPA concentration was comparable with the Km1 value.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results